Company news
Lionco Pharmaceutical Group Co., Ltd. news in 2025
Lionco Pharmaceutical Group Co., Ltd.'s news releases, calls and decks from 2025, newest first.
Announcement on ""Corporate Value and Return Enhancement"" Action Plan
December 30, 2025
Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025
December 24, 2025
Announcement on No Downward Revision of Conversion Price of ""Lionco Convertible Bonds"
December 9, 2025
Announcement on Engagement of Audit Institution for 2025
December 2, 2025
Announcement on Interest Payment for Corporate Convertible Bonds
November 24, 2025
Announcement on Handling of Pledge of Partial Shares of Controlling Shareholder
November 14, 2025
Report for Q3 2025
October 30, 2025
Announcement on Subsidiary’s Prospective Winning in the National Centralized Drug Procurement
October 29, 2025
Announcement on Resolutions of the 1st Meeting of the 5th Board of Directors
October 10, 2025
Announcement on Resolutions of the 21st Meeting of the 4th Board of Supervisors
September 22, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
September 19, 2025
Announcement on Resolutions of the 20th Meeting of the 4th Board of Supervisors
August 22, 2025
Announcement on No Downward Revision of Conversion Price of "Lionco Convertible Bonds" and Suspension and Resumption of Conversion
July 30, 2025
Semi-annual Earnings Preannouncement for 2025
July 14, 2025
Indicative Announcement on Expected Satisfaction of Conversion Price Correction Conditions for "Lionco Convertible Bonds"
July 7, 2025
Announcement on Convening the 2024 Annual and Q1 2025 Performance Briefing
June 18, 2025
Announcement on Follow-up Rating Results of "Lionco Convertible Bonds" in 2025
June 17, 2025
Announcement on Early Return of Raised Funds for Temporary Supplement to Current Capital
June 16, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 23, 2025
Announcement on Obtaining Notice of Approval for Drug Clinical Trials by Wholly-owned Subsidiary
April 28, 2025
Report for Q1 2025
April 25, 2025
Announcement on the Company's and Its Wholly-owned Subsidiaries' Application for Comprehensive Credit Line from Banks in 2025 and Providing Corresponding Guarantee
April 18, 2025
Announcement on Subsidiary's Vecuronium Bromide for Injection Passing Generic Drug Consistency Evaluation
April 11, 2025
Announcement on the Optional Reselling Results of "Lionco Convertible Bonds"
April 10, 2025
The 9th Indicative Announcement on Optional Sell-back of "Lionco Convertible Bonds"
April 7, 2025
The 8th Indicative Announcement on Optional Sell-back of "Lionco Convertible Bonds"
April 3, 2025
The 7th Indicative Announcement on Optional Sell-back of "Lionco Convertible Bonds"
April 2, 2025